Trial Profile
A Phase 2b, Open-Label, Randomized Study of the Safety, Tolerability, and Pharmacodynamic Activity of Lonafarnib With or Without Ritonavir in Patients Chronically Infected With Hepatitis Delta Virus (LOWR-5)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Lonafarnib (Primary) ; Ritonavir
- Indications Hepatitis D
- Focus Therapeutic Use
- Acronyms LOWR-5
- Sponsors Eiger BioPharmaceuticals
- 12 Feb 2021 Status changed from not yet recruiting to withdrawn prior to enrolment, as this study was initially planned to enroll patients in Mongolia. However, due to challenges insetting it up in Mongolia, this study was later determined not to be initiated.
- 07 Feb 2019 Planned End Date changed to 1 Dec 2020.
- 07 Feb 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2020.